Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

huCART-meso

Cell therapy (CAR-T) · Kills target cells, directed at mesothelin (MSLN)

Phase 1 Most advanced trial (none active)
1 Registered trials

What is huCART-meso?

huCART-meso is a chimeric antigen receptor T-cell therapy administered intravenously, with the engineered cells directed against mesothelin. It is studied in pancreatic cancer and serous ovarian cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (CAR-T)
Targets
mesothelin (MSLN) (antigen)
Mechanism
Kills target cells, directed at mesothelin (MSLN)
Therapy area
Oncology
In trials of
TOVX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05057715 Phase 1 Pancreatic Cancer Terminated TOVX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pancreatic CancerSerous Ovarian Cancer

Other drugs acting on MSLN

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.